FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

The Rheumatoid Arthritis Drugs/Therapeutics market revenue was $$ Million USD in 2022, grew to $$ Million USD in 2024, and will reach $$ Million USD in 2032, with a CAGR of $% during 2024-2032.